The estimated Net Worth of Prahlad R. Singh is at least $5.75 Millón dollars as of 15 May 2024. Dr Singh owns over 2,375 units of Revvity stock worth over $362,356 and over the last 8 years he sold PKI stock worth over $526,680. In addition, he makes $4,862,149 as CEO y Pres & Director at Revvity.
Sign up
Dr D PKI stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Revvity stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,375 units of PKI stock worth $273,814 on 15 May 2024.
The largest trade he's ever made was exercising 14,187 units of Revvity stock on 21 December 2022 worth over $694,879. On average, Dr trades about 1,381 units every 91 days since 2017. As of 15 May 2024 he still owns at least 3,143 units of Revvity stock.
You can see the complete history of Dr Singh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Prahlad R. Singh Ph.D. biography
Dr. Prahlad R. Singh Ph.D. is the CEO, Pres & Director at Revvity.
What is the salary of Dr D?
As the CEO y Pres & Director of Revvity, the total compensation of Dr D at Revvity is $4,862,149. There are no executives at Revvity getting paid more.
How old is Dr D?
Dr D is 56, he's been the CEO y Pres & Director of Revvity since . There are 7 older and 14 younger executives at Revvity. The oldest executive at Revvity Inc. is Peter Barrett, 67, who is the Independent Director.
What's Dr D's mailing address?
Prahlad's mailing address filed with the SEC is C/O AMPHENOL CORPORATION, 358 HALL AVENUE, WALLINGFORD, CT, 06492.
Insiders trading at Revvity
Over the last 26 years, insiders at Revvity have traded over $204,298,889 worth of Revvity stock and bought 55,200 units worth $1,110,570 . The most active insiders traders include Alexis P Michas, Gregory L Summe y Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of $6,184,617. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth $332,402.
What does Revvity do?
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
What does Revvity's logo look like?
Complete history of Dr Singh stock trades at Amphenol y Revvity
Revvity executives and stock owners
Revvity executives and other stock owners filed with the SEC include:
-
Dr. Prahlad R. Singh Ph.D.,
CEO, Pres & Director -
Prahlad Singh,
President, Chief Executive Officer, Director -
Joel Goldberg,
Senior Vice President - Administration, General Counsel, Secretary -
James M. Mock,
Sr. VP & CFO -
Joel S. Goldberg,
Sr. VP of Admin., Gen. Counsel & Sec. -
James Mock,
Chief Financial Officer, Senior Vice President -
Deborah Butters,
Chief Human Resource Officer, Senior Vice President -
Tajinder Vohra,
Sr. VP of Global Operations -
Alexandros Michas,
Independent Non-Executive Chairman of the Board -
Samuel Chapin,
Independent Director -
Peter Barrett,
Independent Director -
Pascale Witz,
Independent Director -
Frank Witney,
Independent Director -
Sylvie Gregoire,
Independent Director -
Michel Vounatsos,
Independent Director -
Andrew Okun,
Chief Accounting Officer, Vice President -
Tajinder Vohra,
Senior Vice President, Global Operations -
Daniel Tereau,
Senior Vice President, Strategy and Business Development -
Masoud Toloue,
Sr. VP of Diagnostics -
Miriame Victor,
Sr. VP & Chief Commercial Officer -
Robert Francis Friel,
Advisor -
Stephen Barr Willoughby,
VP of Investor Relations -
Andrew Okun,
VP, Chief Accounting Officer & Treasurer -
Michelle Mc Murry Heath,
Director -
Nicholas A Lopardo,
Director -
James Corbett,
See Remarks -
Alexis P Michas,
Director -
Vicki L Sato,
Director -
Kenton J Sicchitano,
Director -
Robert F Friel,
Chief Financial Officer -
Patrick J Sullivan,
Director -
Frank Anders Wilson,
SVP, CFO & CAO -
John A Roush,
Vice President -
Michael Louis Battles,
VP & Chief Accounting Officer -
Jeffrey D Capello,
Chief Accounting Officer -
Gregory L Summe,
Chairman & CEO -
Katherine A O Hara,
SVP & General Counsel -
Richard F Walsh,
Senior Vice President -
Tamara J Erickson,
Director -
Robert A Barrett,
Sr. Vice President -
Terrance L Carlson,
Sr. VP & General Counsel -
Peter B Coggins,
Sr. Vice President -
John Patrick Murphy,
Sr. Vice President -
John R Letcher,
Senior Vice President, HR -
Jonathan P. Di Vincenzo,
See Remarks -
James C Mullen,
Director -
Maurice H. Tenney,
See Remarks -
Daniel R Marshak,
SVP & CSO -
E Kevin Hrusovsky,
See Remarks -
G Robert Tod,
Director -
Gabriel Schmergel,
Director -
Miriame Victor,
Please See Remarks -
Maxwell Krakowiak,
Please See Remarks